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 I 
ABSTRACT 
Introduction: Triple negative breast cancer (TNBC), lacking human epidermal 
growth factor receptor 2 (HER2), and estrogen receptor (ER) and progesterone 
receptor (PR) expression, are associated with an aggressive natural history 
compared with other disease subtypes. Approximately 70 to 80% of TNBCs more 
frequently overexpress the epidermal growth factor receptor (EGFR), which is 
emerging as a therapeutic target. Photoacoustic imaging (PAI), which can create 
multi-contrast images of living biological structures ranging from organelles to 
organs, has shown great translational potential from bench to bedside due to it 
being relatively inexpensive and convenient for combination with clinical 
ultrasound (US). Gold nanorods (GNs) are extensively used for PAI and NIR-PTT. 
The first aim of this study is to assess the use of US-guided PAI and anti-EGFR 
antibody-conjugated GNs (anti-EGFR-GNs) to detect the EGFR-expressing 
primary tumor mass and regional LN metastases in a mouse model of human 
TNBC. Secondary aim of this study is to prove that anti-EGFR-GNs combined 
with NIR-PTT is an encouraging therapeutic strategy for highly selective cancer 
cell targeting and synergistic anti-cancer activity in aggressive TNBCs. 
Methods: The human breast cancer cell lines (ER+) subtype;MCF-7, HER2+ 
subtype; BT-474, and TN subtype; HCC-578T, HCC-38, HCC-1937, MDA-MB-
453 and MDA-MB-231) were used. The intracellular signaling events were 
evaluated by Western blot. Cell proliferation activity was evaluated by MTT assay. 
 II 
For analysis of apoptotic cell damage, fluorescence of annexin V and propidium 
iodide was measured using flow cytometry. MDA-MB-231 and MCF-7 cells were 
fat pad injected into the back right flank of female BALB/c nude mice (4-5 week 
old) for xenograft tumor model. GNs and anti-EGFR-GNs, 10 nm in diameter and 
41 nm in length used as PAI contrast agents. In vivo real-time US-guided PAI and 
bioluminescence imaging of primary tumor and LN were performed using a 
preclinical Vevo 2100 LAZR Imaging system and IVIS Lumina II Imaging system, 
respectively. For the study of anti-EGFR-GNs-combined NIR-PTT heat (up to 
43°C ) of the culture medium and tumor skin was produced by irradiation of a 
water-filtered infrared A lamp (at 1.5 W/cm2) for 3 min at 48 h post-treatment with 
anti-EGFR-GNs. Hematoxylin and eosin staining, silver enhancement staining, and 
immunostaining were performed on tissue sections.  
Results: Representative western blots showed that TNBC cell lines (Hs578T, 
HCC-38, HCC-1937, MDA-MB-468 and MDA-MB-231) highly expressed EGFR 
whereas the other ER+ (MCF-7) and HER2+ cell lines (BT474) did not. A large 
amount of nanoparticles in the intracellular region was apparent in MDA-MB-231 
cells treated with anti-EGFR-GNs for 24 h, whereas very few nanoparticles in the 
cytoplasm were observed in the MDA-MB-231 cells treated with GNs. In the 
EGFR-targeting study in cultured MCF-7 and MDA-MB-231 cells, selective 
binding of anti-EGFR-GNs on MDA-MB-231 cells which highly expressed EGFR 
was evident, but no binding observed in MCF-7 cells. Intratumor injection of anti-
EGFR-GNs provided a significant enhancement in PA signal in axillary LN of mice 
 III 
after 24h, which correlated histologically with LN metastases with small number of 
cancer cells and anti-EGFR-GNs accumulation. The treatment of anti-EGFR-GNs 
combined with NIR-PTT augmented the induction of HSP70 and cleaved caspase-3 
and decreased Ki-67 and EGFR and EGFR accompanying the strong inhibition of 
intracellular signaling molecules (mTOR, AKT, ERK1/2, and FAK), eventually 
exerting synergic anti-proliferative and apoptotic effects on the MDA-MB-231 
cells. With the help of longitudinal real-time US-guided PAI and bioluminescence 
imaging, the combination of NIR-PTT, after three intravenous injections of anti-
EGFR-GNs in tumor models, resulted in the greatest therapeutic effectiveness of 
almost complete tumor regression without virtually normal tissue damage 
compared with the treatment responses with free anti-EGFR antibodies or anti-
EGFR-GNs alone.  
Conclusions: In conclusion, US-guided PAI technology using anti-EGFR-GNs is 
feasible and highly sensitive for the selective visualization of EGFR-targeted 
primary tumors as well as LN micrometastases in a murine model of human TNBC. 
Anti-EGFR-GNs combined with NIR-PTT is an effective therapeutic strategy for 
TNBC, which enables selective tumor cell targeting through the synergistic 
mechanism of anti-proliferation and apoptosis without side effects and 
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Breast cancer is a heterogeneous disease comprising several biologically distinct 
subtypes, and the majority of breast cancer-related deaths are mainly due to incurable 
metastatic diseases [1]. Triple negative breast cancer (TNBC), lacking human 
epidermal growth factor receptor 2 (HER2), and estrogen receptor (ER) and 
progesterone receptor (PR) expression, are associated with an aggressive natural 
history compared with other disease subtypes. Although triple negative breast cancer 
(TNBC) is a small percentage of all breast cancers, to date, TNBC is one of the most 
challenging types of breast cancer for basic and clinic research because TNBC patients 
display a high risk of relapse, shorter overall survival and limited therapeutic options 
after completion of conventional chemotherapy compared with patients with other 
breast cancer subtypes [2, 3]. Because of the lack of a well-defined clinical strategy, 
chemotherapy is currently the standard-of-care therapy for TNBC patients. Advances 
in the design of strategies for the treatment of TNBC require further elucidation, by 
combined targeted therapy, of the molecular mechanisms underlying TNBC genotypic 
and phenotypic heterogeneity. Approximately 70 to 80% of TNBCs more frequently 
overexpress the epidermal growth factor receptor (EGFR), which correlated with a 
more aggressive phenotype and poor clinical outcomes [4, 5]. Targeting the epidermal 
growth factor receptor (EGFR) has been proposed as a promising imaging biomarker 
for selective detection and treatment of EGFR-positive TNBC including metastases, 
but it is still in the early stages [6-8]. Many clinical studies on TNBC patients using an 
EGFR antibody (cetuximab) and EGFR pathway inhibitors (lapatinib and gefitinib) 
combined with chemotherapy have been evaluated to date, yet EGFR-targeted therapy 




therapeutic strategy to overcome the limitations and complications of current 
treatments of TNBC patients is absolutely required for future clinical trials.  
Non-invasive monitoring of tumors in vivo with biocompatible contrast agents 
including specific targeting molecules after multiple rounds of intravenous 
administration may be capable of being optimized and an efficacious treatment of 
cancer. Photoacoustic imaging (PAI), which can create multicontrast images of living 
biological structures ranging from organelles to organs, has shown great translational 
potential from bench to bedside due to it being relatively inexpensive and convenient 
for combination with clinical ultrasound (US) [10]. Photoacoustic imaging (PAI), 
which uses the phenomena of optical absorption, rapid thermoelastic expansion, and 
acoustic pressure wave generation, has been introduced as a modality that can break 
through the fundamental limitation of the existing pure optical imaging techniques and 
can be performed using various endogenous and exogenous contrast agents [10]. PAI 
systems have been commercialized to meet the growing demand for studying models 
of human disease in small animals due to the availability of relatively inexpensive and 
convenient tools for clinical application. Recently, ultrasound (US)-guided functional 
PAI using exogenous contrast agents was introduced as a promising approach for the 
more sensitive and accurate detection of tumor and lymph node (LN) metastases in 
vivo [11-13]. Gold nanoparticles with strong optical absorption in the near-infrared 
spectral range are developed as PA contrast agents to obtain target-specific information 
on molecular or cellular processes with high sensitivity and specificity, offering 
considerable advances in preclinical research and clinical applications, especially in 
oncology [10, 12]. Gold nanoparticles have been shown to be non-toxic to human cells, 
but are still undergoing initial investigation in clinical cancer trials [14-16]. In recent 




have been proposed as attractive antibody conjugated PA contrast agents to enable the 
selective detection of primary tumor and metastases in vivo [16-18]. GNs with 
particularly near-infrared (NIR) optical properties at wavelengths from 700 to 1000 nm, 
where NIR radiation is able to penetrate the skin without damaging normal tissues, 
have revealed great potential for simultaneously combining selective targeted imaging 
and NIR-mediated photothermal therapy (NIR-PTT) in diverse types of cancer [19-22]. 
In recent years, NIR-PTT using GNs embedded within tumors can cause apoptotic or 
necrotic damage to tumor cells by inducing a localized hyperthermia effect, suggesting 
a promising therapeutic technique with great potential for cancer treatment due to its 
minimal invasiveness and high spatial selectivity [23-29]. To date, GNs heated with an 
NIR light have improved the efficiency and safety of therapy against various solid 
tumors, yet few studies have demonstrated the successful treatment of TNBC. 
Anti-EGFR-GNs with a desired NIR wavelength (approximately 808 nm) are 
ideal for both cancer cell imaging and NIR-PTT. Taken together, US-guided PA 
imaging technology using anti-EGFR-GNs is feasible and highly sensitive to allow 
selective visualization of EGFR-targeted primary tumor as well as LN micrometastases 
in a murine model of human TNBC. We evaluated the feasibility of using anti-EGFR-
GNs combined with NIR-PTT for most effective EGFR-targeted therapy of TNBCs 
with the help of non-invasive and real-time monitoring of selective targeting as well as 






MATERIALS AND METHODS 
1. GNs and anti-EGFR-GNs 
GNs and anti-EGFR-GNs (10 nm×40 nm) were purchased from Nanopartz, Inc. 
(Loveland, CO, USA). In brief, highly stable cetyltrimethylammonium bromide 
(CTAB)-coated GNs with longitudinal plasmon resonance at 808 nm were synthesized 
using a proprietary seed growth method. An SH-terminated branched amine polymer 
manufactured by Nanopartz was used to replace the CTAB. BS3 chemistry was used to 
attach the amine polymer to the primary amine of the anti-EGFR antibodies. It was 
calculated that there are over 100 amines/nm2, which results in loading of 16 antibodies 
per GN. Centrifugation and dialysis against sterile phosphate buffered saline were used 
in all steps of binding and purification. Loading of antibodies was determined using a 
proprietary method incorporating HPLC and UVVIS. Further sterilization and 
endotoxin testing was performed. 
2. Cell culture and reagents 
The following human breast cancer cell lines were obtained from the Korean Cell 
Line Bank (Seoul, Korea): estrogen receptor positive (ER+) cell line (MCF-7), human 
epidermal growth factor receptor 2 amplified (HER2+) cell line (BT-474) and TNBC 
cell lines (Hs578T, HCC-38, HCC-1937, MDA-MB-453 and MDA-MB-231). The 
Hs578T, HCC-38, HCC-1937, MDA-MB-453 and MDA-MB-231 cell lines were 
grown in RPMI1640 medium (WelGENE, Daegu, Korea) containing 10% FBS and 
supplemented with a 1% antibiotic solution containing penicillin and streptomycin. The 
BT-474 and MCF-7 cells were grown in DMEM (WelGENE, Daegu, Korea) 




penicillin and streptomycin. MDA-MB-231-Luc cells stably expressing firefly 
luciferase were established using lentivirus. 
3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
In vitro cell viability and proliferation were assessed using the MTT assay. Briefly, 
5 × 103 cells were allowed to adhere in a high humidity environment in 5% CO2 at 
37 °C in 96-well culture plates. Following a 24 h incubation period, cells were treated 
with GNs, anti-EGFR-GNs, anti-EGFR and EGF for an additional 24 h, 48 h, and 72 h. 
After washing cells with PBS, the medium was replaced with fresh culture medium; 
the MTT solution (final concentration of 1 mg/ml) was added, and the cells were 
incubated for 1 h. At the end of the incubation period, the MTT solution was carefully 
removed, and 150 µl of dimethyl sulfoxide was added to each well. The plates were 
maintained on a rocker shaker for 10 min at 25 °C, and then the amount of MTT 
formazan crystals formed by the viable cells was determined using a spectrophotometer 
based on the absorbance at 540 nm (GE Healthcare, Piscataway, NJ, USA). 
4. Flow cytometry 
For investigating cell damage by anti-EGFR-GN treatment alone or the 
combination anti-EGFR-GNs and NIR-PTT, flow cytometry was performed using a 
FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA). The cells were 
cultured in 6-well plates and subsequently treated with anti-EGFR-GNs, anti-EGFR 
alone or in combination with NIR. The cells were collected and washed twice with ice-
cold PBS containing 1% BSA and 1 mM EDTA and incubated with annexin V and 
propidium iodide (BD Biosciences, San Jose, CA, USA) for 10 min at room 
temperature. Cell damage was assessed concomitantly with flow cytometric evaluation 




measured. The data were analyzed using Cell Quest v3.3 software (BD Biosciences, 
San Jose, CA, USA). 
5. Western blotting analysis  
The cells were lysed in RIPA buffer (Sigma, St. Louis, MO, USA). Proteins were 
separated using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
to nitrocellulose membranes. The membranes were blocked using 5% skim milk in 
Tris-buffered saline containing 0.05% Tween-20 and were incubated with primary 
antibodies overnight at 4°C, followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 
room temperature for 30 min. The following primary antibodies were used in this study: 
anti-EGFR, anti-phospho-AKT, anti-AKT, anti-phospho-ERK1/2, anti-ERK1/2, anti-
phospho-mTOR, anti-mTOR, anti-cleaved caspase-3 and anti-FAK antibodies 
purchased from Cell Signaling Technology (Danvers, MA, USA), anti-phospho-FAK 
and anti-β-actin antibodies purchased from Sigma (St. Louis, MO, US), anti-HSP70 
and anti-HSP90 antibodies purchased from Abcam (Cambridge, MA, USA), and Ki-67 
antibody purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The blots 
were developed using Enhanced Chemiluminescence Reagents (Amersham 
Biosciences, Piscataway, NJ, USA). The relative intensity of the bands observed by 
Western blotting was analyzed using the Image J program. 
6. Immunocytochemistry  
Cells were directly cultured on 8-well chamber slides (Lab-Tek chamber slide), 
fixed in 4% paraformaldehyde, and blocked with 2% bovine serum albumin. After 
washing, the cells were incubated with the anti-EGFR antibody (Cell Signaling 




appropriate secondary antibody for 1 h at room temperature. The proteins were 
visualized with 3,3-diaminobenzidine (DAB), and hematoxylin was used 
as counterstain. The images were acquired using a microscope equipped with a CCD 
camera (Leica, Wetzlar, Germany). 
7. Transmission electron microscopy (TEM)  
For the TEM observation of the intracellular distribution of anti-EGFR-GNs, cells 
were incubated with 10 ml of medium containing 120 pmol/L of anti-EGFR-GNs for 
24 h. Collected cells were fixed with 2.5% glutaraldehyde, treated with 2% osmium 
tetroxide in 0.1 mM cacodylate buffer for 2 h, dehydrated with graded ethanol from 50 
to 100% and propylene oxide and embedded in pure Epon resin at 60 ºC for 3 days. 
Ultrathin sections were cut with glass knives and a Diatome diamond knife (Reichert-
Jung, Vienna, Austria) using an ultramicrotome (RMC MTXL; Tucson, AZ, USA), 
stained with lead citrate and uranyl acetate and observed with a JEM-100 CX 
transmission electron microscope (JEOL, Tokyo, Japan).  
8. Xenograft tumor model 
All animal experiments were approved by the Seoul National University Hospital 
Biomedical Research Institute Animal Care and Use Committee (IACUC). A total of 
46 female Balb/c nude mice (5-6 weeks old) were used for PA and US imaging and 
histological studies. For developing the tumor model, 1×106 viable MDA-MB-231-Luc 
cells were suspended in 0.1 ml of Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) 
and injected into the right fat pad and were injected into the 4th mammary gland of 
mice. Tumor formation was monitored for 4-6 weeks after implantation. To monitor 
primary tumor growth and metastases non-invasively, the luciferase bioluminescence 




Tumor volume was measured with calipers and by US imaging using a modified 
ellipsoidal formula for volume (volume = 1/2[length×width2]) [30]. Indocyanine green 
(ICG) (Sigma-Aldrich, St Louis, MI, USA), non-targeted GN, and anti-EGFR-GNs (10 
nm×40 nm, Nanopartz Inc., Lovel, CO, USA) were dissolved in physiological buffered 
solution. Six healthy mice were randomly assigned to one of 2 experimental groups, 
those that received an ICG injection (n=3) and those that received a GN injection (n=3). 
To identify and image the axillary LN of mice, 30μl of ICG (1 mM, final 5pmol/g 
mouse) or GN (1 nM, final 0.005 pmol/g mouse) was injected into the right forepaw 
pad of each mouse, a 3-4 mm thick section of chicken breast tissue was overlaid on the 
axillary LN, and the mouse was imaged using PA and US imaging.  
When the average tumor volume of 20 tumor-bearing mice injected with either 
MDA-MB-231 cells (MDA-MB-231 tumor) or MCF-7 cells (MCF-7 tumor) reached 
150-200 mm3, the mice were randomly assigned to one of 4 experimental groups and 
were injected intravenously via a tail vein with either 100μl of GN (100 nM, final 0.5 
pmol/g mouse) or anti-EGFR-GNs (100 nM, final 0.5 pmol/g mouse): group 1, MDA-
MB-231 tumor-GN(n=5); group 2, MCF-7 tumor-GN(n=5); group 3, MDA-MB-231 
tumor-anti-EGFR-GN(n=5); and group 4, MCF-7 tumor-anti-EGFR-GN(n=5). The 
mice were then imaged using non-invasive PA and US imaging. 
To identify and image the axillary LN metastases from MDA-MB-231/Luc-tumor-
bearing mice (n=6) at 8 weeks, 100μl of anti-EGFR-GNs (100 nM, final 0.5 pmol/g 
mouse) was injected in to the primary tumor, and 150ug/g of D-luciferin (Promega, 
San Luis Obispo, CA, USA) was injected into the peritoneum, followed by 




To identify and image the Tumor treatment effect, the mice were randomly 
assigned to one of 4 experimental groups: group 1, saline (control) (n=5); group 2, anti-
EGFR-GNs only (n=5); group 3, anti-EGFR-GNs + NIR-PTT (n=5); and group 4, anti-
EGFR only (n=5). The tumor volumes of each group were non-invasively monitored 
after three intravenous injections with either 100 μl of anti-EGFR-GNs (100 nM, final 
of 0.5 pmol/g mouse) or anti-EGFR (100 nM, final of 0.5 pmol/g mouse) and the 
combination with NRI-PTT. 
9. Bioluminescent imaging 
In vivo bioluminescent imaging (BLI) was conducted on the IVIS luminal II system 
(Caliper, Hopkinton, MA, USA) with the use of Living Image acquisition and analysis 
software. The mice were anesthetized with isoflurane after which they were 
intraperitoneally injected with 150 μg/g of the firefly luciferase substrate, D-luciferin 
(Promega, San Luis Obispo, CA, USA). To capture peak intensity, imaging of the 
tumor and LN area was conducted 10 min after the injection of D-luciferin to capture 
the peak intensity, which could well represent the primary tumor volume and the 
metastatic nodule area in the LN. Bioluminescence imaging was performed 4, 5, 6, 7 
and 8 weeks after injection with 1×106 MDA-MB-231/Luc cells stably expressing 
firefly luciferase. 1st, 2nd and 3rd treatment after, bioluminescence imaging was 
performed. The sum of all detected photon counts within tumor was quantified in units 
of mean photons per second per centimeter squared per steradian (p/s/cm2/sr). 
10. PA and US imaging 
All in vivo imaging studies were performed in PA mode using a small-animal high 
resolution Vevo2100 LAZR high frequency US and PA imaging system (FUJIFILM 




55 MHz center frequency linear array with integrated light source) was used to acquire 
all PA and US images. In this system, integrated fiber optic transducers are employed 
to deliver nanosecond laser pulses into deep anatomical targets. Tissues differentially 
and specifically absorb the light causing transient thermoelastic expansions, generating 
acoustic pressure waves, which are detected by 256 sensitive piezoelectric elements. 
Transmitted US pulses are similarly received, generating high-resolution images of 
microscopic anatomical structures. The photoacoustic and spatial dimensions of the 
collected US images were <14 mm (width) by <15 mm (depth). Clear gel was 
centrifuged (to remove air bubbles) and used to provide PA coupling between the 
probe and tumor. The laser was tuned to optical wavelengths from 750 to 850 nm with 
a PA signal gain of 40 dB. Data were collected in triplicate at a frame rate of 5 Hz for 
20 s. Laser fluence, measured by a Nova II power meter with a PE50BB sensor (Ophir-
Spiricon, LLC, North Logan, UT, USA), was between 10 and 20 mJ/cm2; all laser 
energies were below the American National Standards Institute (ANSI) safe exposure 
level for human skin. PA images were averaged eight times, thus suppressing 
uncorrelated noise. Images were analyzed using post-processing software tools 
(FUJIFILM VisualSonics Inc., Toronto, Ontario, Canada). Tumor boundaries, as 
identified on the digitally stored US images, were outlined manually for quantification 
of the PA signal over the area. Each PA image was normalized by the measured 
fluence to correct for the pulse-to-pulse laser energy variations. 
11. NIR-PTT using anti-EGFR-GNs 
Heat was applied using a wIRA (Hydrosun model 750, Hydrosun Medizintechnik 
GmbH, Müllheim, Germany) with a 750 watt halogen lamp and a 780 nm high pass 
filter, yielding a peak output at 820 nm. In vitro NIR-PTT (at 1.5 W/cm2 for 3 min) 




EGFR-GN. Based on our previous study [31], we decided NIR-PTT time point at 
which anti-EGFR-GNs were maximally accumulated into the tumors of mice after 
intravenous injection of anti-EGFR-GNs using serial follow-up PAI. When the average 
tumor volume was 150-200 mm3, a circular mask 1.5 cm in diameter was placed over 
the abdomen to confine the radiation to the tumor region and in vivo NIR-PTT (at 1.5 
W/cm2 for 3 min) at 48 h after intravenous injection of anti-EGFR-GNs (100 nM, final 
0.5 pmol/g mouse) at 3 d-intervals was performed three times. The temperature of 
culture medium and tumor skin was measured using the non-contact infrared 
thermometer gun (BENETECH, Shenzhen, China) 
12. Histological analysis 
Histological analyses of axillary LN and primary tumors were performed. The 
axillary LN was removed after injection of ICG or non-targeted GN. The tumors and 
organs were removed 48 h after the injection of non-targeted GN or anti-EGFR-GNs. 
The metastases detection of axillary LN was removed 48 h after the injection of anti-
EGFR-GNs. The tumors and organs (brain, heart, liver, spleen, kidney, and thigh 
muscle) were removed 48 h after the 3rd treatment with NIR-PTT, The excised tissues 
were fixed with 4% buffered formalin and embedded in paraffin blocks. Tissues were 
sectioned into 4µm-thick sections. Hematoxylin and eosin (H&E) staining, 
immunostaining and immune gold-silver staining (Sigma, St. Louis, MO USA) were 
performed. EGFR expression in tumors and axillary LNs were investigated by 
immunostaining, using antibodies for EGFR (Santa Cruz Biotechnology, Dallas Texas) 
and an appropriate secondary antibody. Cytokeratin expression in isolated axillary LNs 
was investigated by immunostaining, using antibodies for Cytokeratin 8/18/19 (Abcam, 
Cambridge, MA, USA) and an appropriate secondary antibody. After US and PA 




and thigh muscle) and tumors were performed. The tumors and organs of NIR-PTT 
were investigated by immunostaining and TUNEL staining. Immunostaining was 
performed using antibodies for cleaved caspase-3 (Cell Signaling Technology, Danvers, 
MA, USA), Ki-67 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), EGFR (Cell 
Signaling Technology, Danvers, MA, USA) and an appropriate secondary antibody. 
Tissue sections were subsequently stained with counter hematoxylin solution 
(Millipore Ltd., Darmstadt, Germany) for 1 min. Terminal uridine deoxynucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL) staining with the ApopTag 
Peroxidase In Situ Apoptosis Detection Kit (S7100, Millipore) was used to detect 
apoptotic cells. Sections were stained in accordance with kit instructions and the 
following modifications: A 13-minute room-temperature protein digestion in prediluted 
proteinase K was used. Slides were incubated in equilibration buffer for 5 min, then in 
working strength terminal deoxynucleotidyl transferase enzyme at 37°C for 60 min, 
which was followed by a stop/wash step and an anti-digoxigenin peroxidase step, 
which were identical to kit instructions. Color development was with DAB chromogen; 
then, slides were counterstained with hematoxylin. Histological images of stained 
tissues were acquired using a microscope (Leica, Wetzlar, Germany) equipped with a 
CCD camera. The images were saved in TIFF format, and Image J software was used 
to analyze and quantify the expression of cleaved caspase-3, Ki-67 and TUNEL, and 
the percentage of staining was calculated.  
13. Statistical analyses  
For both the in vitro and in vivo data, the means ± standard deviations were 
calculated from at least three independent experiments and statistically evaluated using 






In vivo PAI and histological analysis of axillary LNs of mice. 
Figs. 1a and 1c show representative fusion images of US B-mode and PA-mode 
before and after the injection of ICG and GN. The dynamics of ICG and GN uptake by 
the axillary LN were monitored using PAI, and the contour of the axillary LN region 
can be clearly seen in the fusion images of PA and US B-mode images. The mean PA 
signal amplitude of the axillary LNs of ICG-injected mice pre-injection was 1.60±0.30 
AU, and the PA signal amplitudes at 0.5 h, 1 h, 2 h, 4 h and 24 h post-injection were 
4.68±0.48 AU, 4.89±0.32 AU, 3.83±0.06 AU, 7.50±0.54 AU, 1.95±0.05 AU, 
respectively (Fig. 1b). A significant change in the PA signal in the axillary LN was 
observed at 0.5 h post-injection, indicating significant accumulation of ICG in the 
axillary LN regions, and was strongest 4 h after the injection of ICG (an approximately 
4-fold increase relative to the pre-injection signal, p<0.05). The PA signal measured 
from the axillary LNs just before the injection was similar to that 24 h after the 
injection of ICG. The PA signal amplitudes in the axillary LNs of GN-injected mice 
pre-injection and 4 h, 12 h, 24 h, 48 h and 72 h post-injection were 2.06±0.07 AU, 
3.29±0.17 AU, 6.42±0.45 AU, 9.48±0.73 AU, 11.96±0.59 AU, 9.38±0.59 AU, 
respectively (Fig. 1d). The PA signal amplitude in the LNs of GN-injected mice was 
significantly increased 4 h post-injection and reached a steady state at 48 h post-
injection, indicating a maximal accumulation of GNs in the axillary LN regions (an 
approximately 6-fold increase relative to the pre-injection signal, p<0.05).  
ICG-LNs were observed as dark green in color, and an obvious color change was 




change was observed in ICG-LNs isolated from mice 4 h post ICG injection compared 
with LNs that were not injected (Fig. 1g). A large amount of accumulated GNs in the 
cortex and medulla area of GN-LNs isolated from mice 48 h post-injection was 
detected by silver staining, but there were no histological changes in the tissue as 
detected by H&E staining (Fig. 1h). 
Assessment of selective uptake of anti-EGFR-GNs in the TNBC cell line MDA-
MB-231. 
The TNBC cell lines (HCC-1937 and MDA-MB-231) had high EGFR protein 
expression (as detected by western blot) relative to the HER2-expressing cell lines 
(BT474, HCC1954 and MDA-MB-453), whereas the ER-positive MCF-7 cells did not 
express EGFR (Fig. 2a). Silver staining showed that MDA-MB-231 cells exposed for 
24 h to anti-EGFR-GNs (120 pmol/L) had a specifically and selectively higher 
internalization of the GNs than MCF-7 cells (Fig. 2b). Immunocytochemistry also 
indicated high EGFR expression in MDA-MB-231 cells (Fig. 2c). A large amount of 
nanoparticles in the intracellular region, mostly the endosomes/lysosomes (as indicated 
by the yellow arrows), was apparent in MDA-MB-231 cells treated with anti-EGFR-
GNs for 24 h, whereas very few nanoparticles in the cytoplasm were observed in the 
MDA-MB-231 cells treated with GNs (Fig. 2d). 
In vivo EGFR-targeted PAI and histological analysis of a xenograft tumor mouse 
model.  
The mean PA signal amplitudes in MDA-MB-231 tumors of anti-EGFR-GNs-
injected mice pre-injection and 2 h, 4 h, 8 h, 24 h, 48 h and 72 h post-injection were 




8.60±0.39 AU, 5.95±0.50 AU, respectively. The mean PA signal amplitudes in MCF-7 
tumors of anti-EGFR-GNs-injected mice pre-injection and 2 h, 4 h, 8 h, 24 h, 48 h and 
72 h post-injection were 1.66±0.06 AU, 2.82±0.25 AU,3.06±0.29 AU, 4.93±0.34 AU, 
6.82±0.31 AU, 4.05±0.54 AU, 2.75±0.28 AU, respectively (Figs. 3a-b). The maximal 
value of the PA signals was reached 24 h post-injection in both groups and was 
significantly higher in MDA-MB-231 tumors (approximately 2-fold higher) compared 
with MCF-7 tumors at 48 h and 72 h post-injection (p<0.05). H&E staining did not 
show any necrotic areas in the tumors of either the MCF-7 or MDA-MB-231 group 
(Fig. 3c upper). MDA-MB-231 tumor tissue showed higher EGFR expression than 
MCF-7 tumor tissue (Fig. 3c middle). Silver staining showed a large amount of anti-
EGFR-GNs accumulated in the MDA-MB-231 tumors, whereas no anti-EGFR-GNs 
were seen in the MCF-7 tumors (Fig. 3c lower).  
However, in MCF-7 and MDA-MB-231 tumors injected with non-targeted GNs, 
the no significant difference in PA signals between the 2 groups at 2 h, 4 h, 24 h, 48 h 
and 72 h of the time points was observed (Figs. 4a-b). Non-targeted GNs, though being 
less accumulated in MDA-MB-231 tumors compared to anti-EGFR-GNs, can be used 
in in vivo PAI application for generally detecting tumor due to the enhanced 
permeability and retention (EPR) effect that is property by which non-targeted GNs 
tend to accumulate in tumor tissue much more that they do in normal tissues. Silver 
staining showed that accumulation of non-targeted GNs were not seen in the MCF-7 
and MDA-MB-231 tumors at 72 h (Fig. 4c lower). 
In vivo EGFR-targeted PAI and histological analysis of LN metastases.  
An obviously enhanced PA signal (3.67±0.18 AU) was detected in axillary LNs 




with anti-EGFR-GNs (0.5 pmol/g mouse) compared with that of the pre-injection 
(1.53±0.12 AU) (Figs. 5a-c). No significant PA signal change was observed in non-
metastatic axillary LNs of the MDA-MB-231-Luc tumor-bearing mice (n=4) after 
intratumoral injection with anti-EGFR GNs (pre vs post, 1.57±0.15 AU vs 1.61±0.13 
AU) (Figs. 5b-c). In vivo and ex vivo strong bioluminescence signals were obtained in 
primary tumors, but no signal was detected in the axillary LNs showing the enhanced 
PA signals using an IVIS imaging system (Fig. 5d). As expected, H&E staining as well 
as EGFR and Cytokeratin 8/18/19 immunostaining of axillary LN isolated from a 
mouse with a strong PA signal revealed the presence of MDA-MB-231-Luc cells in the 
cortex and medulla area of the LN (Fig. 5e upper and middle). Silver staining and 
showed that the anti-EGFR-GNs injected into the tumor drained to the axillary LN 
harboring metastases, confirming the correlation with the increased PA signals (Fig. 5e 
lower). In contrast, no cancer cells and anti-EGFR-GNs were detected in those axillary 
LNs that showed no changes in PA signals (Fig. 5f). 
Analysis of proliferation and apoptotic activity by anti-EGFR-GNs-NIR PTT in 
cultured MDA-MB-231 and MCF-7 cells.  
The growth of MDA-MB-231 cells treated with anti-EGFR-GNs or free anti-EGFR 
was significantly decreased at 48 and 72 h compared with those of the untreated control 
(Fig. 6a; P < 0.01 and P < 0.01, respectively). Figs. 6b and 6c show the flow 
cytometric analysis of annexin V and propidium iodide (PI) staining on MDA-MB-231 
cells after treatment with anti-EGFR-GN or free anti-EGFR for 48 h and subsequent 
treatment with NIR-PTT for 3 min. Irradiation with NIR light increased the culture 
medium up to 40°C, thereby resulting in approximately 9.34 ± 0.39% of apoptotic 




anti-EGFR led to 27.83 ± 0.47% or 21.27 ± 1.41% apoptotic death (P < 0.01). After 
treatment with free anti-EGFR, subsequent treatment with NIR-PTT augmented the 
apoptotic death (36.73 ± 2.20%, P < 0.001). More importantly, anti-EGFR-GN+NIR-
PTT led to an increase in therapeutic temperature to 43°C, consequently resulting in 
the most effective apoptotic Analysis of the fundamental mechanisms of anti-
proliferation and apoptosis triggered by anti-EGFR-GN combined with NIR-PTT in 
cultured MDA-MB-231 cells. The representative western blots and the relative analysis 
of HSP70, HSP90, Ki-67, cleaved caspase-3 and EGFR are shown in Figs 6d and e. 
The significant induction of HSP70 was the most obvious in cells treated with anti-
EGFR-GN+NIR-PTT (782.13 ± 46.54 %) and anti-EGFR-GN (520.43 ± 57.93 %) (Fig. 
6e; P <0.001). On the other hand, there is no difference in HSP90 levels in all cells. A 
significant decrease in proliferation marker Ki-67 was observed in cells after the 
treatment with anti-EGFR-GN alone (9.06 ± 1.05 %) or anti-EGFR-GN+NIR-PTT 
(6.18 ± 4.33 %) relative to the untreated control, whereas the significant increase in the 
apoptotic marker cleaved caspase-3 was observed in cells after the treatment with anti-
EGFR-GN alone (259.08 ± 29.84 %) or anti-EGFR-GN+NIR-PTT (455.66 ± 70.46 %) 
(Fig. 6e; P <0.001). A significant decrease of EGFR was evident in cells treated with 
the anti-EGFR-GN (16.49 ± 8.03 %) and anti-EGFR-GNs+NIR-PTT (5.89 ± 2.00 %,) 
(Fig. 6e; P <0.001). Figs. 6f and 6g show the representative western blots and the 
relative analysis of phosphorylated mTOR, FAK, AKT and ERK1/2. When compared 
with those of untreated control, the decrease of phosphorylated mTOR in NIR-PTT 
alone, anti-EGFR-GNs alone and anti-EGFR-GN+NIR-PTT was 61.25 ± 15.22 %, 
21.84 ± 8.21 %, and 8.51 ± 1.92 %, respectively (Fig. 6g; P < 0.01 or P< 0.001). The 
phosphorylated FAK decreased up to 50.14 ± 3.79 %, 17.67 ± 5.83 %, and 7.67± 1.51 % 




relative to that of untreated control (Fig. 6g; P < 0.001). Phosphorylated AKT in cells 
treated with NIR-PTT alone, anti-EGFR-GN alone and anti-EGFR-GN+NIR-PTT 
relative to untreated control was decreased by 93.24 ± 12.26 %, 18.83 ± 2.18 %, and 
11.50 ± 4.81 %, respectively (Fig. 6g; P < 0.001). Phosphorylated ERK1/2 treated by 
NIR-PTT alone, anti-EGFR-GN alone and anti-EGFR-GN+NIR-PTT was also 
significantly decreased by 59.46 ± 6.67 %, 23.04 ± 7.70%, and 6.37 ± 2.18 %, 
respectively, compared with those of the untreated control (Fig. 6g; P < 0.001). Anti-
EGFR-GN combined with NIR-PTT resulted in synergistic promotion of anti-
proliferative and apoptotic signals and was more effective for suppressing the 
phosphorylation of mTOR, FAK, AKT and ERK1/2 compared to those of NIR-PTT 
alone or anti-EGFR-GN alone (42.61 ± 0.95%, P < 0.001).  
The treatment with anti-EGFR or anti-EGFR-GN did not affect the growth in 
MCF-7 cells, which do not express EGFR (Fig. 7a). The treatment with anti-EGFR or 
anti-EGFR-GN did not cause death of MCF-7 cells, but NIR-PTT did cause apoptotic 
death (12.23 ± 0.31%). The anti-EGFR-GN+NIR-PTT did not augment apoptotic death 
of MCF-7 cells (Figs. 7 b-c). Our results revealed that anti-EGFR-GN combined with 
NIR-PTT worked by selectively and synergistically inducing anti-proliferation and 
apoptosis in MDA-MB-231 cells but not in MCF-7 cells. 
In vivo US-guided PAI and BLI to monitor the therapeutic response in xenograft 
tumor models during treatment with anti-EGFR-GN combined with NIR-PTT.  
Fig. 8a shows the therapy strategy for xenograft tumors. When the tumors reached 
a volume of 150-200 mm3 at 2 weeks, NIR-PTT was performed at 48 h after the three 
intravenous injections of anti-EGFR-GNs at 4-day intervals because anti-EGFR-GNs 




24 h and 48 h and tumors was monitored by longitudinal follow-up US-guided PAI and 
BLI. Fig. 8b shows representative color Doppler images and US-guided PAIs obtained 
from tumors in each group. Treatment with anti-EGFR, anti-EGFR-GN and anti-
EGFR-GN+NIT-PTT did not cause significant differences in the body weights of mice 
after three trails, and the damage of normal tissues compared to those of untreated mice, 
suggesting the absence of physical distress over the course of the experiment. As 
shown in Fig. 8c, enhanced PA signal amplitudes in tumors of control and anti-EGFR-
injection mice were not observed, yet greatly enhanced PA signals in tumors were 
evident in anti-EGFR-GN-injected mice, indicating the selective accumulation of anti-
EGFR-GNs into the tumor mass. The mean PA signal amplitude of tumors was 
approximately 9.18 ± 0.56 to 10.00 ± 0.71 AU at 48 h after first injection with anti-
EGFR-GNs but gradually decreased after two and three treatments with anti-EGFR-
GN (8.46 ± 0.30, 6.52 ± 0.19 AU) or anti-EGFR-GN+NIR-PTT (3.21 ± 0.1, 1.24 ± 
0.08 AU), which may selectively reflect EGFR-positive tumor cell damage or tumor 
vascular insult during therapeutic intervention in tumors with the anti-EGFR or NIR-
PTT. 
Figs. 9a and 9b show representative BLI of tumors and the quantification of 
the photon flux measured from tumors in each group. An obvious decrease of 
photonic flux of tumors at the indicated times after the 1st, 2nd and 3rd treatment with 
anti-EGFR (0.64 ± 0.26, 0.84 ± 0.13 and 0.15 ± 0.11 photons/s/cm2/sr), anti-EGFR-GN 
(1.40 ± 0.24, 0.23 ± 0.29 and 0.08 ± 0.03 photons/s/cm2/sr) and anti-EGFR-GN+NIR-
PTT (0.22 ± 0.41,  0.07 ± 0.11 and  0.04 ± 0.04 photons/s/cm2/sr) was observed 
compared with those of untreated controls (1.20 ± 0.42, 1.10 ± 0.28 and , 1.95 ± 0.17 
photons/s/cm2/sr), respectively (Fig. 9b; P < 0.001). Bioluminescence activity in 




disappeared, which indicates that most tumor cells are not viable. A significantly 
continuous decrease of tumor volumes was observed in the anti-EGFR-treated mice 
(137.30 ± 10.42 mm3), anti-EGFR-GN-treated mice (117.72 ± 22.19 mm3) and anti-
EGFR-GN+NIR-PTT-treated mice (21.94 ± 9.41 mm3) during the third post-treatment 
compared to those of control mice (254.48 ± 10.60 mm3), whereas tumor volumes of 
the control group continued to increase gradually (Fig. 9c; P < 0.001). The anti-EGFR-
GN combined with NIR-PTT showing strong therapeutic effects is most encouraging, 
resulting in successful tumor regression in vivo at the third post-treatment compared to 
that of the initial tumor volume. 
Histological analysis of tumor tissues treated with anti-EGFR-GN combined with 
NIR-PTT.  
The gross images of tumor tissues revealed the smallest residual tumor volume in 
anti-EGFR-GN+NIR-PTT groups (Fig. 10a). From analysis of H&E images, the 
necrotic area in residual tumor tissues of the anti-EGFR-GN+NIR-PTT group was not 
observed (Fig. 10b). Consistent with the in vitro results of cultured cells assessed by 
western blot analysis, representative immunohistochemical images showed higher 
cleaved caspase-3 and TUNEL staining as well as lower Ki-67 and EGFR staining in 
the anti-EGFR-GN+NIR-PTT tumors than in the other tumors (Fig. 10c). TUNEL 
staining was significantly higher in the anti-EGFR-GN tumors (1.93 ± 0.42%) and anti-
EGFR-GN+PTT tumors (5.2 ± 0.66%) but not in anti-EGFR tumors (0.67 ± 0.15%) 
relative to control tumor (0.67 ± 0.25%) (Fig. 10d; P < 0.001). Cleaved caspase-3 
staining was also significantly higher in tumors treated with anti-EGFR (21.0 ±3.61%), 
anti-EGFR-GN (44.33 ± 5.86%) and anti-EGFR-GN+NIR-PTT (73.33 ± 10.69%) 




was significantly lower in the anti-EGFR (18 ± 3.0%), anti-EGFR-GNs (8.67 ± 2.08%) 
and anti-EGFR-GN+NIR-PTT tumors (3.66 ± 1.52%) compared to that in control cells 
(30 ± 5.0%) (Fig. 10f; P < 0.001). In addition, EGFR staining was significantly lower 
in the anti-EGFR (3.4 ± 0.75%), anti-EGFR-GN (1.33 ± 0.20%) and anti-EGFR-
GN+NIR-PTT tumors (0.83 ± 0.35%) compared with that in control tumor (17±4.0%) 
(Fig. 10g; P < 0.001). Histological analysis revealed that anti-EGFR-GN combined 
with NIR-PTT eventually led to the most effective therapy for tumor regression 
through augmentation of the synergic mechanisms of anti-proliferation and apoptosis. 
From analysis of H&E staining, we did not observe damage or histological alteration of 
the liver, spleen or kidney of each group (Fig 10h). In the silver staining, even though 
accumulated anti-EGFR-GNs were not detected in liver and spleen, a few remained in 













PAI using various exogenous contrast agents (methylene blue, ICG and GNs) is a 
rapidly emerging non-ionizing and noninvasive imaging technology that integrates the 
merits of strong optical contrast with high spatial resolution to image the course and 
flow of lymphatic vessels as well as to selectively detect breast tumors, including 
metastases [10-13]. PAI easily integrates the clinical US imaging system and has 
shown tremendous potential in accurately detecting primary tumor and LN metastases 
while simultaneously providing structural, functional and molecular information at 
clinically relevant penetration depths [10]. Because breast cancer cells often invade 
regional LN receiving the drainage from a tumor, accurate detection of regional LN 
metastases can help to determine the stage of the breast cancer and develop an 
appropriate treatment plan for the breast cancer patient [18, 32-34]. Moreover, a 
sentinel node biopsy guided by ICG or PAI can avoid postoperative complications, 
such as seroma formation, lymphedema, and limited motion, of an axillary LN 
dissection [35, 36]. In an effort to improve on accurate identification and safe 
dissection of metastatic LNs, non-invasive imaging modalities including 
bioluminescence imaging, positron emission tomography (PET), US and magnetic 
resonance imaging (MRI) have been tested in animal models and patients but currently 
lack the specificity and sensitivity to discriminate between metastatic and normal LNs. 
Our results showed that non-invasive EGFR-targeted US-guided PAI is sensitive 
enough to detect the primary tumor and metastatic LNs in a mouse model of human 
TNBC. 
Multifunctional contrast agents loaded with specific antibodies and therapeutic 




degradation, inadequate pharmacokinetics and tissue accessibility, of therapeutic 
antibodies and drugs, thereby reducing non-specific side effects and enabling higher 
dose delivery to target tissues over expressing the cell surface receptor [10, 15]. Rod-
shape gold nanoparticles characterized by enhanced optical absorption and 
photostability are attractive PA contrast agents because of their production of strong 
PA signals as well as their ability to conjugate biomolecules to them for PAI. In the 
present study, we highlighted the potential of using PAI combined with intravenous 
anti-EGFR-GNs (0.5 pmol/g mouse) injections to selectively visualize EGFR-
expressing breast cancer cells. In our study, the intravenously injected GN 
concentration is lower than previously reported doses [16, 37]. Moreover, the amount 
of anti-EGFR antibody (0.92 μg/g animal) loaded in the GNs was lower compared with 
a clinical trial using cetuximab [6] but was a sufficient amount for specific and 
selective targeting of EGFR-expressing cancer cells. The maximum accumulation of all 
tested nanoparticles after intravenous injection occurred in the liver and spleen. In 
agreement with most published reports [16], the very small amount of GNs 
accumulated in the liver and spleen was detected by silver staining.  
Luke GP et. al. showed the in vivo application of PAI to non-invasively detect the 
LN micrometastases (<50μm) using intratumoral injection with 1.6 pmol of spherical 
gold nanoparticles targeted to the EGFR oral cancer animal models, but the LN 
micrometastatic foci (<50μm) was able to detected by using bioluminescence imaging 
method [13]. Very recently, although the functional spectroscopic PAI to measure the 
blood oxygen saturation in the LN led to less sensitivity and specificity to discriminate 
metastatic LN as compared to PAI using exogenous PA contrast agents, this approach 
might open up the suitable possibility for clinical applications[38]. Recently, TNBC 




translational and clinical studies for emerging targeted TNBC therapies have therefore 
been facilitated by increased understanding of the aberrant gene expression regulating 
growth and survival [4, 5]. EGFR, which is detected to be highly expressed in 70% of 
TNBCs, has represented a clinically relevant molecular target for TNBC patients [9, 
39]. The anti-EGFR antibodies bind to EGFR, thereby blocking its downstream 
signaling through its internalization and degradation, and can lead to cytotoxicity [40]. 
Many clinical Phase I/II investigations for TNBC patients have tried using FDA-
approved anti-EGFR antibody Cetuximab combined with chemotherapy [6, 7, 9, 41], 
yet the results have been somewhat disappointing.  
In our study, PAI by intratumoral injection of 0.5 pmol/g mouse anti-EGFR-GNs, 
which is a significantly lower amount compared with that of previous reports [42] 
clearly identified small colonies of EGFR-expressing cancer cells that spread to the 
axillary LNs, even though bioluminescence imaging technology did not detect the 
cancer cell in LNs. Our result showed that anti-EGFR-GNs-enhanced PAI is more 
sensitive than bioluminescence imaging for the early detection of breast cancer cells 
that have migrated to regional LNs. Our studies combining US-guided PAI with anti-
EGFR-GNs may be able to achieve simultaneous sensitivity and specificity values 
approaching 100% to discriminate LN micrometastases from normal LN.  
The anticancer therapy of multifunctional GNs loaded with cetuximab and a low 
dose of gemcitabine in an orthotopic pancreatic cancer model was superior to that of 
the antibody alone, drug alone or combination of the two [42], suggesting that anti-
EGFR-GNs can be used for treating EGFR-expressing breast cancer cell LN metastases. 
Although the concentration of anti-EGFR-GNs in this study is below the previously 
reported amount exhibiting toxicity, GNs are not yet accepted for widespread clinical 




of anti-EGFR-GNs used as a clinical therapy need to be conducted because particles 
larger than 5 to 6 nm are not easily cleared from the body [16]. Our results suggest that 
non-invasive EGFR-targeted PAI is a relevant approach for use in the clinic to improve 
the selective and effective targeted delivery of chemotherapeutics into EGFR-
expressing tumors and to guide real-time surgery of LN micrometastases and residual 
tumors with EGFR-expressing cancer cells, following some alterations in the system to 
make it functional and safe for humans.  
In the present study, we have proven an improvement in the therapeutic efficacy of 
anti-EGFR antibody treatment by intravenous injection with GNs to effectively 
delivery anti-EGFR antibodies into TNBCs, which showed strong inhibition of the 
EGFR-mediated signaling pathway and apoptotic cell death. Most importantly, the 
anti-EGFR-GNs combined with NIR-PTT strategy exhibited the most successful 
therapeutic efficacy by selectively targeting TNBC cells and tumors without any 
damage to normal tissues through the augmented mechanism of anti-proliferative and 
apoptotic activity.  
PTT is a noninvasive cancer therapy technique that promotes tumor destruction by 
altering the function of many structural and enzymatic proteins within cancer cells, 
thereby leading to successful destruction of the cancer cells [43, 44]. Considerable 
research is being directed towards developing nanoparticles, including GNs, for a wide 
range of biomedical applications, such as molecular diagnosis and targeted therapy via 
site-specific targeted delivery and stabilizing labile molecules including antibodies 
from degradation [15, 16, 22]. GNs have been brought to the forefront of cancer 
research in recent years because of their convenient synthesis and surface 
modifications for specific molecular delivery as well as tunable optical properties for 




NIR spectrum (700−1000 nm), which is the most advantageous wavelength region 
suitable for biological applications owing to its high capability of deeper penetration 
into animal tissues in this optical window, have recently been developed and 
successfully applied with NIR-PTT to cause damage to localized primary and 
metastatic cancer [19, 23, 46]. Anti-EGFR-GNs with a desired optical absorption in the 
NIR spectrum (808 nm) have unique properties that provide the potential for 
simultaneously selectively targeting PAI and NIR-PTT applications in vivo. However, 
to the best of our knowledge, NIR-PTT using anti-EGFR-GNs has not yet been applied 
to TNBCs in vitro and in vivo. Moreover, the detailed biological mechanisms of 
cellular therapeutic response to anti-EGFR-GNs combined with NIR-PTT have not 
been explored.  
In our study, TEM images revealed that a large amount of anti-EGFR-GNs are 
taken up by MDA-MB-231 cells, resulting in the accumulation in endosomes or 
lysosomes, consistent with many studies with regards to nanoparticles being 
endocytosed by cells, particularly when attached to a receptor ligand such as an 
internalized antibody, and accumulate in endosomes or lysosomes [16]. We found here 
that significant uptake of anti-EGFR-GNs suppressed the proliferation activity of 
MDA-MB-231 cells compared to that with non-targeted GNs, which is involved in 
blocking EGFR-mediated signaling molecules (mTOR, AKT, FAK and ERK) and 
suppressing EGFR and Ki-67 through the selective and effective delivery of the anti-
EGFR-antibodies. The possible modes of cell death triggered by PTT include necrosis 
and apoptosis. More specifically, high-energy irradiation can lead to necrosis and low-
energy irradiation can promote apoptosis. In our conditions, with exposure to NIR light, 
anti-EGFR-GNs induced mild hyperthermia, defined in cancer treatment as a rise in 




photothermal agents. More importantly, we demonstrated that anti-EGFR-GNs 
combined with NIR-PTT induced an increase in HSP70 and cleaved caspase-3, 
augmented the blockade of the phosphorylation of mTOR, AKT, FAK and ERK and 
the suppression of EGFR and Ki-67 in cultured MDA-MB-231 cells, which suggesting 
the molecular mechanism of synergistic apoptotic and anti-proliferative activity, not 
necrosis, is involved in tumor cell death. Taken together in an in vitro study, PTT 
combined with NIR light and anti-EGFR-GNs has proven to be a selective and 
effective therapy in TNBC cell lines expressing EGFR. Anti-EGFR-GNs combined 
with NIR-PTT, resulting from in vitro studies, offers a favorable therapeutic strategy 
for EGFR-expressing TNBC tumors.  
Anti-EGFR-GNs, resulting from the regression of tumor volumes in xenograft mice 
models, enhanced the therapeutic effect compared with that of free anti-EGFR 
antibodies, thus offering the feasibility of an excellent nanoplatform for in vivo therapy 
applications. One of the most promising directions in PTT is the use of GNs with peak 
transmission at approximately 800 nm and 10 to 100 nm in diameter because skin, 
tissues, and hemoglobin have transmission windows from 650 to 900 nm, and the 
bloodstream circulation times of GNs are increased, which causes improved tumor 
accumulation from an intravenous administration and leads to better effects of PTT [10, 
17, 23, 46]. We speculate that anti-EGFR-GNs are excellent for NIR-PTT applications 
in vivo due to their properties of peak absorbance at 808 nm and long circulation time. 
As we expected, anti-EGFR-GNs combined with NIR-PTT led to remarkably greater 
tumor regression compared with treatment with either anti-EGFR antibody injection 
alone or anti-EGFR-GNs injection alone, significantly reducing proliferation activity 
(low Ki-67 level) and inducing apoptotic activity (high cleaved caspase-3 and TUNEL-




In conclusion, US-guided PAI technology using anti-EGFR-GNs is feasible and 
highly sensitive. It allows for the selective visualization of EGFR-targeted primary 
tumors as well as LN micrometastases in a murine model of human TNBC. Our study 
demonstrates that anti-EGFR-GNs are feasible diagnosis and therapy agents for 
simultaneously applying selective EGFR-targeted PAI and NIR-PTT to aggressive 
EGFR-positive cancers due to their properties of selective tumor cell targeting, long 
circulation time and desired optical absorption upon NIR irradiation light. By the 
exposure of EGFR-positive TNBC cells and tumors treated with anti-EGFR-GNs to 
NIR light, blockade of the EGFR-mediated intracellular signal pathway (low 
phosphorylated mTOR, AKT, ERK and FAK levels) involved in cell proliferation and 
survival as well as the strong anti-proliferative (low Ki-67 level) and apoptotic activity 
(high cleaved caspase-3 and TUNEL staining levels) of tumor cells and tumor tissues 
were observed. Anti-EGFR-GNs represent reliable and reproducible photothermal 
agents on favorable NIR lights. Anti-EGFR-GNs combined with NIR-PTT is a feasible 
and effective therapeutic strategy, which enables selective tumor cell targeting through 
the synergistic mechanism of anti-proliferation and apoptosis without side effects and 
complications compared with previous conventional therapy strategy. US-guided PAI 
and anti-EGFR-GNs combined with NIR-PTT would be a novel theranostic system to 
simultaneously investigate non-invasive and longitudinal diagnosis and therapy of 








Figure 1： Analysis of US-guided photoacoustic (PA) images and histology of the 
axillary LN of mice injected with ICG or gold nanorods (GN). (a) Non-invasive and 
dynamic fusion of US and PA images of the axillary LN region before and 0.5 h, 1 h, 2 
h, 4 h and 24 h after ICG injection (5 pmol/g mouse). (b) Plot of PA signal amplitude 
in axillary LNs versus pre- and post-injection time of ICG. (c) Non-invasive and 
dynamical fusion of US and PA images of axillary LN region before and 4 h, 12 h, 24 
h, 48 h and 72 h after GN injection (0.005 pmol/g mouse). (d) Plot of PA signal 
amplitude in axillary LNs versus pre- and post-injection time of GN. The results 
represent the mean±standard deviation in the ICG-mice group (n=5) and the GN-mice 
group (n=5), *p<0.05, **p<0.01, Arbitrary units (AU). (e, f) Photographs of isolated 
axillary LN before and after injection of ICG or GN. (g) H&E staining of 
microsectioned axillary LN isolated from mice 4 h post-injection of ICG. (h) H&E 
staining and silver staining of microsectioned axillary LN isolated from mice at 48 h 
post-injection of GN. The control (Cont) is a microsectioned axillary LN without 





Figure 2. Analysis of EGFR expression and selective uptake of anti-EGFR-GNs in 
breast cancer cells. (a) EGFR expression in MCF-7, BT-474, Hs578T, HCC-38, 
HCC-1937, MDA-MB-453 and MDA-MB-231 human breast cancer cell lines (by 
western blot). (b) Representative immunocytochemistry for EGFR in MDA-MB-231 
cells and MCF-7 cells. (c) Silver staining of MCF-7 and MDA-MB-231 cells incubated 
with or without 120 pmol/L of anti-EGFR-GNs for 24 h. Control (Cont) was incubated 
without 120pmol/L of anti-EGFR-GNs. (d) TEM images of MDA-MB-231 cells 
treated with GNs or anti-EGFR-GNs for 24 h. TEM images revealed a large amount of 
endocytic uptake of anti-EGFR-GNs (yellow arrows) by MDA-MB-231 cells. Scale 





Figure 3. US-guided PAI and histology acquired in MCF-7 and MDA-MB-231 
primary tumors of mice intravenously injected with anti-EGFR-GNs. (a) Non-
invasive and dynamical fusion of US and PA images of MCF-7 and MDA-MB-231 
tumors before and 2 h, 4 h, 8 h, 24 h, 48 h and 72 h after intravenous injection with 
anti-EGFR-GNs (0.5 pmol/g mouse). (b) Plot of PA signal amplitude in MCF-7 and 
MDA-MB-231 tumors versus pre- and post-injection of anti-EGFR-GNs. The results 
represent the mean±standard deviation in the MCF-7-mice group (n=5) and MDA-MB-
231-mice group (n=5). **p<0.01, Arbitrary units (AU). (c) H&E staining, EGFR 
immunostaining and silver staining of microsectioned MDA-MB-231 and MCF-7 
primary tumors isolated from mice 48 h post-injection of anti-EGFR GN. Scale bar: 





Figure 4. US-guided PAI and histology acquired in MCF-7 and MDA-MB-231 
primary tumors of mice intravenously injected with GNs. (a) Non-invasive and 
dynamical fusion of US and PA images of MCF-7 and MDA-MB-231 tumors before 
and 2 h, 4 h, 8 h, 24 h, 48 h and 72 h after intravenous injection with non-targeted GNs 
(0.5pmol/g mouse). (b) Plot of PA signal amplitude in MCF-7 and MDA-MB-231 
tumors versus pre-and post-injection of non-targeted GNs. The results represented the 
mean±standard deviation in the MCF-7-mice group (n=5) and MDA-MB-231-mice 
group (n=5). **p<0.01, Arbitrary units (AU). (c) H&E staining and silver staining of 
microsectioned MDA-MB-231 and MCF-7 primary tumor isolated from mice 48 h 





Figure 5. In vivo EGFR-targeted PAI and histological analysis of LN metastases (a, 
b) Non-invasive and dynamical fusion of US and PA images of axillary LN metastases 
and non-LN metastases in MDA-MB-231-Luc tumor-bearing mice 24 h after 
intratumoral injection with anti-EGFR-GNs (0.5 pmol/g mouse). (c) Plot of PA signal 
amplitude in axillary LN at pre- and post-injection of anti-EGFR-GNs. The results 
represent the mean±standard deviation in the LN metastases mice group (n=2) and 
non-LN metastases mice group (n=4), Arbitrary units (AU). (d) In vivo (left) and ex 
vivo (right) bioluminescence imaging of MDA-MB-231-Luc tumor-bearing mice 
injected intraperitoneally with D-luciferin (150 μg/g mouse). Red and white circles 
indicate the excised primary tumor and axillary LN from ex vivo bioluminescence 
imaging. (e, f) H&E staining, EGFR and cytokeratin 8/18/19 immunostaining and 
silver staining of microsectioned axillary LNs isolated from mice at 48 h post-injection 





Figure 6. Analysis of cell proliferative and apoptotic action caused by anti-EGFR-
GN combined NIR-PTT in cultured MDA-MB-231 cells. (a) Analysis of cell growth 
(mean±S.D., n=5) assessed by MTT assay in MDA-MB-231 cells treated with anti-
EGFR-GNs (120 pM) and anti-EGFR antibodies (0.22 µg/ml) for 24, 48 and 72 h. (b) 
Representative flow cytometric analysis of Annexin V and PI MDA-MB-231 cells 
treated with anti-EGFR-GNs (120 pM) and anti-EGFR antibodies (0.22 µg/ml) for 24 h 
and combined NIR-PTT for 3 min. (c) Analysis of apoptotic cell death (mean±S.D., 
n=4) assessed by flow cytometry. (d, f) Representative western blot of heat shock 
proteins (HSP90, HSP70), EGFR, Ki-67, cleaved caspase-3 and EGFR-mediated 
intracellular signaling molecules (mTOR, FAK, AKT, ERK1/2) in MDA-MB-231 cells 
treated with NIR-PTT, anti-EGFR-GNs and anti-EGFR-GNs combined with NIR-PTT. 
(e, g) Data (mean±S.D., n=5) were obtained from western blot experiments. **P < 0.01, 





Figure 7. Analysis of cell proliferative and apoptotic action caused by anti-EGFR-
GN combined NIR-PTT in cultured MCF-7 cells. (a) Analysis of cell growth 
(mean±S.D., n=5) assessed by MTT assay in MCF-7 cells treated with anti-EGFR-GNs 
(120 pM) and anti-EGFR antibodies (0.22 µg/ml) for 24, 48 and 72 h. (b) 
Representative flow cytometric analysis of Annexin V and PI in MCF-7 cells treated 
with anti-EGFR-GNs (120 pM) and anti-EGFR antibodies (0.22 µg/ml) for 24 h and 
combined NIR-PTT for 3 min. (c) Analysis of apoptotic cell death (mean±S.D., n=4) 





Figure 8. Analysis of PAI-guided NIR-PTT using anti-EGFR-GN combined in 
xenograft tumors. (a) Scheme for the in vivo experimental procedure.  (b) 
Representative serial US-guided PAI of tumors in mice receiving 2nd and 3rd EGFR-
GNs combined with NIR-PTT treatments. Left and right images show 2D color 
Doppler images and PAI superimposed on the B-mode real-time US in each group. (c) 
PA signals (mean±S.D.) were measured from 5 tumors of each group at pre-, and 1st, 





Figure 9. Analysis of bioluminescence imaging (BLI) to monitor the therapeutic 
response in xenograft tumor models during treatment. (a) Representative non-
invasive bioluminescence imaging in tumors of each mouse group. (b) Photon flux 
(mean±S.D.) was measured from 5 tumors of each group at pre-, 1st, 2nd and 3rd 
treatments. (c) Tumor volumes (mean±S.D.) were measured from 5 tumors of each 





Figure 10. Histological analysis of tumor tissues treated with anti-EGFR-GN 
combined with NIR-PTT. (a) Gross images of the tumors isolated from each mouse 
group. (b) Representative H&E images of the tumors isolated from each mouse group. 
Necrotic areas (N) in residual tumor tissues. (c) Representative immunohistochemistry 
images of TUNEL, cleaved caspase-3, Ki-67 and EGFR staining. (d e, f, g) TUNEL-, 
cleaved caspase-3-, Ki-67- and EGFR-positive populations (mean±S.D.) were analyzed 
from 5 tumor sections of each group. (h) H&E and silver staining of kidney, liver and 
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서론: 에스트로겐 수용체(estrogen receptor: ER), 프로게스테론 
수용체(progesterone receptor: PR) 발현 및 HER-2/neu 종양유전자 증폭이 
없는 삼중음성 유방암은 유방암 아형 중 예후가 가장 나쁘다. 
표피성장인자수용체(epidermal growth factor receptor, EGFR)는 70-80%의 
삼중음성유방암에서 발현이 증가되어 있어 표적 진단과 치료를 위한 
유전자로 제시되어 있다. 광음향영상은 다양한 생체내 또는 체외 광흡수 
물질들을 감지하여 생체의 해부학적, 기능적, 대사적, 그리고 
분자유전적인 특징을 영상으로 보여줌으로써, 비침습적 방법으로 
고해상도 분자세포 영상 및 분광학 정보를 얻을 수 있으며 초음파와 
결합이 용이하여 기초 연구뿐만 아니라 임상에서도 활용 가능한 
영상기법이다.  본 연구에서는 EGFR항체접합 골드나노로드(anti-EGFR-
GNs)와 광음향/초음파 일체형 영상기기를 사용하여 EGFR과발현한 
유방암과 국소 림프절전이를 표적하여 진단하고, 근적외선을 병용하여 
비침습적 열치료 효과를 실시간 모니터링하고 정량적으로 평가하였다. 
실험방법: 사람유방암 세포주 (ER양성; MCF-7, HER2양성; BT-474, 
삼중음성; Hs578T, HCC-38, HCC-1937, MDA-MB-468, MDA-MB-231)를 
사용하였고 Western blot을 통해 각 세포에서의 EGFR 발현양을 
확인하였다. MCF-7과 MDA-MB-231세포에 각각 GNs 와 anti-EGFR-
GNs를 처리하여 EGFR표적지향성을 평가하였고 근적외선 열치료 병용 
전후 세포 내 신호변화, 세포증식 및 세포자멸을 Western blot, MTT 및 
유세포분석을 통하여 대조군과 비교 분석하였다. MCF-7과 MDA-MB-
231세포를 면역결핍마우스 (BALB/c nude)의 피하에 이식하여 종양을 




꼬리정맥으로 투여하여 광음향/초음파영상을 획득하고 광음향영상 
신호강도를 분석하였다. 또한 MDA-MB-231 종양의 국소림프절전이 
여부를 진단하기 위하여 MDA-MB-231 종양내에 anti-EGFR-GNs를 투여 
후 림프절에서 광음향영상 신호 강도와 생체발광영상 신호 강도를 
분석하였다. 마지막으로 삼중음성유방암 진단과 치료효과를 동시에 
평가하기 위해서 anti-EGFR-GNs 와 근적외선 열치료를 단독 및 결합하여 
체외와 체내에서 치료효과를 비교 분석하였다. 체내 모든 실험은 광음향 
초음파 일체형 장비인 Vevo 2100 LAZR을 사용하였고 영상후처리 
소프트웨어를 사용하여 통계분석 하였다. 영상 촬영이 끝난 후 조직을 
적출하여 H&E염색, 은염색, 조직면역염색 및 TUNEL염색을 진행하였다. 
결과: Western blot을 통해 삼중음성유방암세포(Hs578T, HCC-38, HCC-
1937, MDA-MB-468 과 MDA-MB-231)가 다른 아형 유방암세포 (MCF-7, 
BT-474)에 비해 EGFR 발현양이 높은 것을 확인하였고 
EGFR표적지향성을 평가한 결과 anti-EGFR-GNs가 GNs에 비해, MDA-
MB-231에서 선택적으로 결합 되는 것을 광음향 영상, 전자현미경이미지 
및 면역염색을 통하여 확인하였다. MDA-MB-231 종양과 MCF-7 종양에서 
GNs와 anti-EGFR-GNs를 투여후 광음향신호를 분석한 결과 MDA-MB-
231 종양에서는 GNs를 투여한 그룹에 비해 anti-EGFR-GNs을 투여한 
종양에서 유의하게 EGFR표적 조영증강 효과를 관찰할 수 있었으나 
MCF-7 종양에서는 두 그룹에서 유의한 차이가 없었다. 또한, MDA-MB-
231 세포의 국소 림프절전이가 있는 마우스에서도 anti-EGFR-GNs 주사 
24시간후, 전이림프절에서 현저한 조영증강 효과를 관찰할 수 있었다. 
anti-EGFR항체 단독 치료, anti-EGFR-GNs 단독 치료, anti-EGFR-GNs 와 
근적외선 열치료를 병용하여 치료한 그룹을 체외와 생체내에서 
치료효과를 분석한 결과, anti-EGFR-GNs 단독 치료한 그룹보다 열치료를 
병용한 그룹에서 HSP70과 cleaved caspase-3를 더 많이 유도했고 Ki-67과 




FAK 인신화를 현저하게 차단하는 것을 확인하였다. 광음향/초음파와 
생체발광 영상으로 실시간 모니터링한 결과 anti-EGFR-GNs 와 열치료를 
병용한 그룹에서 종양성장이 억제되고 종양크기가 가장 많이 감소하여 
성공적인 종양 치료효과를 확인하였다. 
결론: 본 연구 결과를 통해 anti-EGFR-GNs와 광음향영상기법을 이용하여 
삼중음성유방암을 선택적으로 표적 진단할 수 있었고 국소 림프절 
전이여부도 확인 할 수 있었으며 또한 근적외선 열치료를 병용하여 
치료효과도 모니터링 할 수 있었다. 본 연구에서 제시한 종양표적항체-
나노로드 접합체를 사용한 광음향영상진단법과 근적외선 열치료의 
병용치료법은 향후 삼중음성유방암의 표적 진단과 치료에 사용될 수 있을 
것이다.  
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